Atopic dermatitis and skin diseaseDupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis
Key words
Abbreviations used
Cited by (0)
Supported by Regeneron Pharmaceuticals and Sanofi (NCT01259323, NCT01385657).
Disclosure of potential conflict of interest: J. D. Hamilton and A. R. Radin are employed by Regeneron, have patents through Regeneron, and receive stock/stock options as part of their compensation. M. Suárez-Fariñas has received research support from and has consultant arrangements with Regeneron. I. Cardinale and X. Li have received research support from Regeneron. A. Kostic and N. Graham are employed by Regeneron and receive stock/stock options as part of their compensation. J. E. Ming and G. Pirozzi are employed by Sanofi and receive stock/stock options as part of their compensation. J. G. Krueger has received grants paid to the institution and personal fees from Novartis, Pfizer, Janssen, Lilly, Merck, Kadmon, Dermira, Boehringer, BMS, and Paraxel during the conduct of the study; grants paid to the institution from Amgen, Innovaderm and Kyowa; and personal fees from Serono, Biogen Idec, Delenex, AbbVie, Sanofi, Baxter, Xenoport, and Kineta.G. D. Yancopoulos is a board member for Regeneron, is employed as Chief Science Officer for Regeneron, and receives stock/stock options as part of his compensation. E. Guttman-Yassky has received research support from Regeneron, BMS, Janssen, Celgene, and Leo Pharma; has board memberships with Regeneron, Sanofi, Celgene, GlaxoSmithKline/Stiefel, MedImmune, and Leo Pharma; and has consultant arrangements with Regeneron, Celgene, BMS, Dermima, MedImmune, GlaxoSmithKline/Stiefel, and Galderma. The rest of the authors declare that they have no relevant conflicts of interest.
- ∗
These authors contributed equally to this work.